*NeuroNexus, Facilitating CDRH's Participation
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- Not on record
- Points of contact
-
- CDRH Acquisition Liaison cdhracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring services to establish and operate NeuroNexus, a cross-center collaboratory within the Center for Devices and Radiological Health, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research to facilitate coordinated review of medical products for neurological and psychiatric diseases and conditions. The primary objectives include expediting development and review of novel therapies and diagnostics through shared knowledge and cross-center communication, engaging with government, academic, clinical, patient, and industry partners, supporting congressionally mandated neuroscience programs including the Act for ALS and the National Alzheimer's Prevention Act, and tracking neuroscience-related activities across centers. The estimated solicitation release date is July 1, 2026, with an estimated award date of January 1, 2027.
The estimated award value ranges from $1.5 million to $3 million. Inquiries should be directed to cdhracquisitions@fda.hhs.gov.
Forecast text
NeuroNexus is a collaboratory of review groups within the Center for Devices and Radiological Health (CDRH), Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER) who review medical products used in the treatment, diagnosis, or management of neurological and psychiatric diseases and conditions. FDA is intending to announce this new cross-Center initiative in October 2027.The NeuroNexus collaboratory will formalize a program to connect the 3 FDA centers with the following main objectives:Expedite the development and review of novel therapies and diagnostics intended to treat, diagnose, or manage neurological and psychiatric disorders through shared knowledge, review efficiency, and cross-center communication.Engage with other government, academic, clinical professional, patients, and industry partners to obtain up-to-date knowledge and activities on identified project areas.Support congressionally mandated neuroscience programs, such as the Act for ALS, Neurology Drug Program, National Alzheimer's Prevention Act, etc.Share and track information on neuroscience related activities within each center
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast